GAMP 5 introduced a science-based, risk-based approach. This philosophy dictates that the level of validation effort should be proportional to the risk the system poses to product quality, patient safety, and data integrity. By focusing resources on critical aspects of the system, organizations can streamline their processes without compromising compliance. This approach aligns with guidelines such as the FDA’s "Guidance for Industry: Part 11, Electronic Records; Electronic Signatures" and ICH Q9 (Quality Risk Management), fostering a more efficient and scientifically justifiable validation lifecycle.